View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 13, 2016

Nuvo to begin Phase III trial of Pennsaid 2% to treat acute ankle sprains

US-based pharmaceutical company Nuvo has announced its intention to conduct a Phase III trial of Pennsaid 2% in Germany to treat acute ankle sprains.

US-based pharmaceutical company Nuvo has announced its intention to conduct a Phase III trial of Pennsaid 2% in Germany to treat acute ankle sprains.

Pennsaid 2% is a topical, non-steroidal, anti-inflammatory drug (NSAID) composed of 2% diclofenac sodium.

It is a gel formulation applied in a metered dose pump bottle.

The trial is designed to support regulatory approvals in the European Union, Canada and Australia.

"The trial incorporates what we learned from a similar trial conducted in 2015 that produced encouraging results, and we believe Pennsaid 2% can show positive results in this setting."

Nuvo president and CEO John London said: "The trial incorporates what we learned from a similar trial conducted in 2015 that produced encouraging results, and we believe Pennsaid 2% can show positive results in this setting.

"In particular, we have changed the primary endpoint (pain on movement) to the third day after initial treatment, which was a secondary endpoint whereby Pennsaid 2% demonstrated statistical significance in the 2015 trial."

The placebo-controlled, multi-centre trial plans to involve approximately 130 patients who are experiencing a grade I or grade II ankle sprain.

During the trial, the patients will be randomly assigned on a double-blind basis to an active arm or a placebo arm and will be administered to either Pennsaid 2% or a placebo, which consists of all the constituents of Pennsaid 2% except its active ingredient diclofenac sodium.

It will be applied on the patients' injured ankles twice a day for a duration of eight days.

The trial is primarily focused on achieving a reduction in pain of movement (POM) after three days, while the secondary endpoints are to reduce tenderness, ankle function, ankle swelling and achieve an overall clinical benefit of the medication.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena